Portal de Periódicos da CAPES

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

2017; National Comprehensive Cancer; Volume: 15; Issue: 4 Linguagem: Inglês

10.6004/jnccn.2017.0050

1540-1413

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Lucian R. Chirieac, Thomas A. D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, M.C. Dobelbower, Robert C. Doebele, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P. Lackner, Michael Lanuti, Ticiana Leal, Leah J. Leisch, Rogerio Lilenbaum, Jules Lin, Billy W. Loo, Renato Martins, Gregory A. Otterson, Karen L. Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Steven Swanson, Kurt W. Tauer, Stephen C. Yang, Kristina M. Gregory, Miranda Hughes,

Lung Cancer Diagnosis and Treatment

This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.